ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PRCT PROCEPT BioRobotics Corporation

81.17
0.39 (0.48%)
21 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
PROCEPT BioRobotics Corporation NASDAQ:PRCT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.39 0.48% 81.17 80.81 91.02 82.275 79.41 79.41 1,288,040 05:00:02

PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024

26/11/2024 9:05pm

GlobeNewswire Inc.


PROCEPT BioRobotics (NASDAQ:PRCT)
Historical Stock Chart


From Dec 2024 to Dec 2024

Click Here for more PROCEPT BioRobotics Charts.

PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time.

A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The HYDROS™ Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:Matt BacsoVP, Investor Relations and Business Operationsm.bacso@procept-biorobotics.com

1 Year PROCEPT BioRobotics Chart

1 Year PROCEPT BioRobotics Chart

1 Month PROCEPT BioRobotics Chart

1 Month PROCEPT BioRobotics Chart

Your Recent History

Delayed Upgrade Clock